Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Gilead initiated with an Equal Weight at Wells Fargo » 16:33
12/08/21
12/08
16:33
12/08/21
16:33
GILD

Gilead

$69.72 /

+0.04 (+0.06%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal initiated coverage of Gilead Sciences with an Equal Weight rating and $72 price target. The company's cancer expansion is going well and Trodelvy will likely work in the TROPiCS-02 trial, but this may already be priced in, Bansal tells investors in a research note. The analyst says Gilead's HIV business "appears to be slowing down" and that its post-pandemic recovery "may not be enough to propel it back to double-digit growth."

ShowHide Related Items >><<
GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

GILD Gilead
$69.72 /

+0.04 (+0.06%)

Conference/Events
SABCS to hold a symposium » 04:55
12/08/21
12/08
04:55
12/08/21
04:55
AZN

AstraZeneca

$54.79 /

-0.625 (-1.13%)

, BYSI

BeyondSpring

$4.67 /

+0.575 (+14.06%)

, CHRS

Coherus Biosciences

$17.95 /

+0.33 (+1.87%)

, CNTX

Context Therapeutics

$5.51 /

-0.08 (-1.43%)

, DSNKY

Daiichi Sankyo

$24.24 /

+0.535 (+2.26%)

, ESALY

Eisai

$60.56 /

-0.11 (-0.18%)

, EXAS

Exact Sciences

$83.51 /

+2.61 (+3.23%)

, GILD

Gilead

$69.68 /

+0.18 (+0.26%)

, GH

Guardant Health

$95.44 /

+6.8 (+7.67%)

, INCY

Incyte

$66.74 /

+1.73 (+2.66%)

, JAGX

Jaguar Health

$1.32 /

+0.155 (+13.30%)

, LLY

Eli Lilly

$245.03 /

-1.165 (-0.47%)

, MGNX

MacroGenics

$17.18 /

+0.46 (+2.75%)

, MRK

Merck

$72.27 /

-1.15 (-1.57%)

, MYGN

Myriad Genetics

$26.06 /

+1.07 (+4.28%)

, NTRA

Natera

$92.59 /

+6.45 (+7.49%)

, NEO

NeoGenomics

$33.92 /

+2.33 (+7.38%)

, NVS

Novartis

$80.70 /

+0.18 (+0.22%)

, OLMA

Olema Oncology

$11.02 /

+0.52 (+4.95%)

, OCX

OncoCyte

$2.40 /

+0.09 (+3.90%)

, ONCY

Oncolytics

$1.67 /

+0.06 (+3.73%)

, PBYI

Puma Biotechnology

$3.08 /

+0.11 (+3.70%)

, PFE

Pfizer

$51.72 /

+0.22 (+0.43%)

, RHHBY

Roche

$49.77 /

+0.04 (+0.08%)

, SNY

Sanofi

$47.91 /

+0.34 (+0.71%)

, SGEN

Seagen

$146.46 /

+0.435 (+0.30%)

, SPPI

Spectrum

$1.54 /

+0.17 (+12.41%)

, VCYT

Veracyte

$41.21 /

+3.66 (+9.75%)

, VERU

Veru

$6.36 /

+0.175 (+2.83%)

, VTRS

Viatris

$12.40 /

-0.04 (-0.32%)

, ZYME

Zymeworks

$18.26 /

+0.025 (+0.14%)

San Antonio Breast Cancer…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZYME Zymeworks
$18.26 /

+0.025 (+0.14%)

VTRS Viatris
$12.40 /

-0.04 (-0.32%)

VERU Veru
$6.36 /

+0.175 (+2.83%)

VCYT Veracyte
$41.21 /

+3.66 (+9.75%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.91 /

+0.34 (+0.71%)

SGEN Seagen
$146.46 /

+0.435 (+0.30%)

RHHBY Roche
$49.77 /

+0.04 (+0.08%)

PFE Pfizer
$51.72 /

+0.22 (+0.43%)

PBYI Puma Biotechnology
$3.08 /

+0.11 (+3.70%)

ONCY Oncolytics
$1.67 /

+0.06 (+3.73%)

OLMA Olema Oncology
$11.02 /

+0.52 (+4.95%)

OCX OncoCyte
$2.40 /

+0.09 (+3.90%)

NVS Novartis
$80.70 /

+0.18 (+0.22%)

NTRA Natera
$92.59 /

+6.45 (+7.49%)

NEO NeoGenomics
$33.92 /

+2.33 (+7.38%)

MYGN Myriad Genetics
$26.06 /

+1.07 (+4.28%)

MRK Merck
$72.27 /

-1.15 (-1.57%)

MGNX MacroGenics
$17.18 /

+0.46 (+2.75%)

LLY Eli Lilly
$245.03 /

-1.165 (-0.47%)

JAGX Jaguar Health
$1.32 /

+0.155 (+13.30%)

INCY Incyte
$66.74 /

+1.73 (+2.66%)

GILD Gilead
$69.68 /

+0.18 (+0.26%)

GH Guardant Health
$95.44 /

+6.8 (+7.67%)

EXAS Exact Sciences
$83.51 /

+2.61 (+3.23%)

ESALY Eisai
$60.56 /

-0.11 (-0.18%)

DSNKY Daiichi Sankyo
$24.24 /

+0.535 (+2.26%)

CNTX Context Therapeutics
$5.51 /

-0.08 (-1.43%)

CHRS Coherus Biosciences
$17.95 /

+0.33 (+1.87%)

BYSI BeyondSpring
$4.67 /

+0.575 (+14.06%)

AZN AstraZeneca
$54.79 /

-0.625 (-1.13%)

AZN AstraZeneca
$54.79 /

-0.625 (-1.13%)

12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
BYSI BeyondSpring
$4.67 /

+0.575 (+14.06%)

12/02/21 Evercore ISI
BeyondSpring price target lowered to $25 from $95 at Evercore ISI
12/02/21 Jefferies
Jefferies cuts BeyondSpring to Hold, slashes target to $5 after plinabulin CRL
12/02/21 Jefferies
BeyondSpring downgraded to Hold from Buy at Jefferies
12/01/21 BofA
BeyondSpring downgraded to Underperform from Buy at BofA
CHRS Coherus Biosciences
$17.95 /

+0.33 (+1.87%)

11/09/21 H.C. Wainwright
Coherus Biosciences price target lowered to $30 from $36 at H.C. Wainwright
07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
CNTX Context Therapeutics
$5.51 /

-0.08 (-1.43%)

DSNKY Daiichi Sankyo
$24.24 /

+0.535 (+2.26%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
ESALY Eisai
$60.56 /

-0.11 (-0.18%)

10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
EXAS Exact Sciences
$83.51 /

+2.61 (+3.23%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
GILD Gilead
$69.68 /

+0.18 (+0.26%)

12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
GH Guardant Health
$95.44 /

+6.8 (+7.67%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
INCY Incyte
$66.74 /

+1.73 (+2.66%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
JAGX Jaguar Health
$1.32 /

+0.155 (+13.30%)

07/07/21
Fly Intel: Top five analyst initiations
07/07/21 Cantor Fitzgerald
Jaguar Health initiated with an Overweight at Cantor Fitzgerald
02/24/21 Ladenburg
Jaguar Health transferred with Buy, $3.75 target at Ladenburg
LLY Eli Lilly
$245.03 /

-1.165 (-0.47%)

11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
MGNX MacroGenics
$17.18 /

+0.46 (+2.75%)

11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
06/07/21 Wedbush
MacroGenics price target lowered to $34 from $39 at Wedbush
MRK Merck
$72.27 /

-1.15 (-1.57%)

12/07/21
Fly Intel: Top five analyst downgrades
12/07/21 Guggenheim
Guggenheim downgrades Merck on Keytruda concentration, low pipeline visibility
12/07/21 Guggenheim
Merck downgraded to Neutral from Buy at Guggenheim
11/29/21
Fly Intel: Top five analyst downgrades
MYGN Myriad Genetics
$26.06 /

+1.07 (+4.28%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
NTRA Natera
$92.59 /

+6.45 (+7.49%)

11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
10/19/21 Canaccord
Natera Prospera Lung launch to continue momentum, says Canaccord
10/14/21 Cowen
Natera coverage transferred at Cowen
08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
NEO NeoGenomics
$33.92 /

+2.33 (+7.38%)

12/07/21 Needham
NeoGenomics price target lowered to $41 from $48 at Needham
11/05/21 Morgan Stanley
Morgan Stanley downgrades NeoGenomics, sees limited near-term upside
11/05/21 Morgan Stanley
NeoGenomics downgraded to Equal Weight from Overweight at Morgan Stanley
10/14/21 Raymond James
NeoGenomics upgraded to Outperform from Market Perform at Raymond James
NVS Novartis
$80.70 /

+0.18 (+0.22%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
OLMA Olema Oncology
$11.02 /

+0.52 (+4.95%)

12/06/21 Cowen
Olema Oncology assumed with an Outperform at Cowen
12/06/21 Cowen
Olema Oncology assumed with an Outperform at Cowen
10/11/21
Olema Oncology participates in a conference call with JPMorgan
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
OCX OncoCyte
$2.40 /

+0.09 (+3.90%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
ONCY Oncolytics
$1.67 /

+0.06 (+3.73%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
PBYI Puma Biotechnology
$3.08 /

+0.11 (+3.70%)

09/28/21
Fly Intel: Top five analyst upgrades
09/28/21 Citi
Puma Biotechnology upgraded to Buy after 40% selloff at Citi
09/27/21 Citi
Puma Biotechnology upgraded to Buy from Neutral at Citi
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
PFE Pfizer
$51.72 /

+0.22 (+0.43%)

12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
RHHBY Roche
$49.77 /

+0.04 (+0.08%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
SNY Sanofi
$47.91 /

+0.34 (+0.71%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
SGEN Seagen
$146.46 /

+0.435 (+0.30%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
VCYT Veracyte
$41.21 /

+3.66 (+9.75%)

11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
06/15/21 Raymond James
Veracyte initiated with an Outperform at Raymond James
VERU Veru
$6.36 /

+0.175 (+2.83%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VTRS Viatris
$12.40 /

-0.04 (-0.32%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
ZYME Zymeworks
$18.26 /

+0.025 (+0.14%)

11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
10/06/21 Jefferies
Zymeworks initiated with a Hold at Jefferies
09/13/21 Raymond James
Zymeworks data continue to outperform Herceptin, says Raymond James
08/05/21 H.C. Wainwright
Zymeworks price target lowered to $44 from $55 at H.C. Wainwright
ZYME Zymeworks
$18.26 /

+0.025 (+0.14%)

VTRS Viatris
$12.40 /

-0.04 (-0.32%)

VERU Veru
$6.36 /

+0.175 (+2.83%)

VCYT Veracyte
$41.21 /

+3.66 (+9.75%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.91 /

+0.34 (+0.71%)

SGEN Seagen
$146.46 /

+0.435 (+0.30%)

RHHBY Roche
$49.77 /

+0.04 (+0.08%)

PFE Pfizer
$51.72 /

+0.22 (+0.43%)

PBYI Puma Biotechnology
$3.08 /

+0.11 (+3.70%)

ONCY Oncolytics
$1.67 /

+0.06 (+3.73%)

OCX OncoCyte
$2.40 /

+0.09 (+3.90%)

NVS Novartis
$80.70 /

+0.18 (+0.22%)

NTRA Natera
$92.59 /

+6.45 (+7.49%)

MYGN Myriad Genetics
$26.06 /

+1.07 (+4.28%)

MRK Merck
$72.27 /

-1.15 (-1.57%)

MGNX MacroGenics
$17.18 /

+0.46 (+2.75%)

LLY Eli Lilly
$245.03 /

-1.165 (-0.47%)

INCY Incyte
$66.74 /

+1.73 (+2.66%)

GILD Gilead
$69.68 /

+0.18 (+0.26%)

GH Guardant Health
$95.44 /

+6.8 (+7.67%)

EXAS Exact Sciences
$83.51 /

+2.61 (+3.23%)

BYSI BeyondSpring
$4.67 /

+0.575 (+14.06%)

AZN AstraZeneca
$54.79 /

-0.625 (-1.13%)

  • 22
    Jul
  • 20
    Oct
  • 18
    Feb
  • 05
    Feb
  • 05
    Feb
  • 07
    Jan
ZYME Zymeworks
$18.26 /

+0.025 (+0.14%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.91 /

+0.34 (+0.71%)

RHHBY Roche
$49.77 /

+0.04 (+0.08%)

PFE Pfizer
$51.72 /

+0.22 (+0.43%)

NVS Novartis
$80.70 /

+0.18 (+0.22%)

NEO NeoGenomics
$33.92 /

+2.33 (+7.38%)

MRK Merck
$72.27 /

-1.15 (-1.57%)

LLY Eli Lilly
$245.03 /

-1.165 (-0.47%)

GILD Gilead
$69.68 /

+0.18 (+0.26%)

GH Guardant Health
$95.44 /

+6.8 (+7.67%)

EXAS Exact Sciences
$83.51 /

+2.61 (+3.23%)

ESALY Eisai
$60.56 /

-0.11 (-0.18%)

AZN AstraZeneca
$54.79 /

-0.625 (-1.13%)

ZYME Zymeworks
$18.26 /

+0.025 (+0.14%)

VCYT Veracyte
$41.21 /

+3.66 (+9.75%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.91 /

+0.34 (+0.71%)

SGEN Seagen
$146.46 /

+0.435 (+0.30%)

RHHBY Roche
$49.77 /

+0.04 (+0.08%)

PFE Pfizer
$51.72 /

+0.22 (+0.43%)

PBYI Puma Biotechnology
$3.08 /

+0.11 (+3.70%)

OLMA Olema Oncology
$11.02 /

+0.52 (+4.95%)

NVS Novartis
$80.70 /

+0.18 (+0.22%)

NTRA Natera
$92.59 /

+6.45 (+7.49%)

NEO NeoGenomics
$33.92 /

+2.33 (+7.38%)

MRK Merck
$72.27 /

-1.15 (-1.57%)

MGNX MacroGenics
$17.18 /

+0.46 (+2.75%)

LLY Eli Lilly
$245.03 /

-1.165 (-0.47%)

JAGX Jaguar Health
$1.32 /

+0.155 (+13.30%)

INCY Incyte
$66.74 /

+1.73 (+2.66%)

GILD Gilead
$69.68 /

+0.18 (+0.26%)

GH Guardant Health
$95.44 /

+6.8 (+7.67%)

EXAS Exact Sciences
$83.51 /

+2.61 (+3.23%)

CNTX Context Therapeutics
$5.51 /

-0.08 (-1.43%)

BYSI BeyondSpring
$4.67 /

+0.575 (+14.06%)

AZN AstraZeneca
$54.79 /

-0.625 (-1.13%)

VTRS Viatris
$12.40 /

-0.04 (-0.32%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

PFE Pfizer
$51.72 /

+0.22 (+0.43%)

NVS Novartis
$80.70 /

+0.18 (+0.22%)

MRK Merck
$72.27 /

-1.15 (-1.57%)

LLY Eli Lilly
$245.03 /

-1.165 (-0.47%)

INCY Incyte
$66.74 /

+1.73 (+2.66%)

GILD Gilead
$69.68 /

+0.18 (+0.26%)

BYSI BeyondSpring
$4.67 /

+0.575 (+14.06%)

AZN AstraZeneca
$54.79 /

-0.625 (-1.13%)

Tuesday
Conference/Events
SABCS to hold a symposium » 10:22
12/07/21
12/07
10:22
12/07/21
10:22
AZN

AstraZeneca

$53.65 /

-1.76 (-3.18%)

, BYSI

BeyondSpring

$4.59 /

+0.5 (+12.22%)

, CHRS

Coherus Biosciences

$17.68 /

+0.06 (+0.34%)

, CNTX

Context Therapeutics

$5.63 /

+0.04 (+0.72%)

, DSNKY

Daiichi Sankyo

$23.70 /

-1.46 (-5.80%)

, ESALY

Eisai

$60.67 /

+0.47 (+0.78%)

, EXAS

Exact Sciences

$83.65 /

+2.75 (+3.40%)

, GILD

Gilead

$69.06 /

-0.44 (-0.63%)

, GH

Guardant Health

$94.94 /

+6.3 (+7.11%)

, INCY

Incyte

$66.58 /

+1.57 (+2.42%)

, JAGX

Jaguar Health

$1.23 /

+0.065 (+5.58%)

, LLY

Eli Lilly

$243.25 /

-2.945 (-1.20%)

, MGNX

MacroGenics

$17.22 /

+0.5 (+2.99%)

, MRK

Merck

$72.16 /

-1.26 (-1.72%)

, MYGN

Myriad Genetics

$26.16 /

+1.17 (+4.68%)

, NTRA

Natera

$92.20 /

+6.06 (+7.04%)

, NEO

NeoGenomics

$34.37 /

+2.78 (+8.80%)

, NVS

Novartis

$80.49 /

-0.03 (-0.04%)

, OLMA

Olema Oncology

$11.28 /

+0.78 (+7.43%)

, OCX

OncoCyte

$2.42 /

+0.11 (+4.76%)

, ONCY

Oncolytics

$1.68 /

+0.07 (+4.35%)

, PBYI

Puma Biotechnology

$3.00 /

+0.03 (+1.01%)

, PFE

Pfizer

$51.75 /

+0.25 (+0.49%)

, RHHBY

Roche

$49.73 /

+0.38 (+0.77%)

, SNY

Sanofi

$47.51 /

-0.06 (-0.13%)

, SGEN

Seagen

$148.08 /

+2.06 (+1.41%)

, SPPI

Spectrum

$1.54 /

+0.17 (+12.41%)

, VCYT

Veracyte

$40.67 /

+3.12 (+8.31%)

, VERU

Veru

$6.32 /

+0.14 (+2.27%)

, VTRS

Viatris

$12.50 /

+0.065 (+0.52%)

, ZYME

Zymeworks

$18.97 /

+0.735 (+4.03%)

San Antonio Breast Cancer…

San Antonio Breast Cancer Symposium: SABCS 2021 to be held on December 7-10. Webcast Link

ShowHide Related Items >><<
ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

VTRS Viatris
$12.50 /

+0.065 (+0.52%)

VERU Veru
$6.32 /

+0.14 (+2.27%)

VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SGEN Seagen
$148.08 /

+2.06 (+1.41%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

ONCY Oncolytics
$1.68 /

+0.07 (+4.35%)

OLMA Olema Oncology
$11.28 /

+0.78 (+7.43%)

OCX OncoCyte
$2.42 /

+0.11 (+4.76%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

NTRA Natera
$92.20 /

+6.06 (+7.04%)

NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

JAGX Jaguar Health
$1.23 /

+0.065 (+5.58%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

ESALY Eisai
$60.67 /

+0.47 (+0.78%)

DSNKY Daiichi Sankyo
$23.70 /

-1.46 (-5.80%)

CNTX Context Therapeutics
$5.63 /

+0.04 (+0.72%)

CHRS Coherus Biosciences
$17.68 /

+0.06 (+0.34%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

12/02/21 Evercore ISI
BeyondSpring price target lowered to $25 from $95 at Evercore ISI
12/02/21 Jefferies
Jefferies cuts BeyondSpring to Hold, slashes target to $5 after plinabulin CRL
12/02/21 Jefferies
BeyondSpring downgraded to Hold from Buy at Jefferies
12/01/21 BofA
BeyondSpring downgraded to Underperform from Buy at BofA
CHRS Coherus Biosciences
$17.68 /

+0.06 (+0.34%)

11/09/21 H.C. Wainwright
Coherus Biosciences price target lowered to $30 from $36 at H.C. Wainwright
07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
CNTX Context Therapeutics
$5.63 /

+0.04 (+0.72%)

DSNKY Daiichi Sankyo
$23.70 /

-1.46 (-5.80%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
ESALY Eisai
$60.67 /

+0.47 (+0.78%)

10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
GILD Gilead
$69.06 /

-0.44 (-0.63%)

12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
GH Guardant Health
$94.94 /

+6.3 (+7.11%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
INCY Incyte
$66.58 /

+1.57 (+2.42%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
JAGX Jaguar Health
$1.23 /

+0.065 (+5.58%)

07/07/21
Fly Intel: Top five analyst initiations
07/07/21 Cantor Fitzgerald
Jaguar Health initiated with an Overweight at Cantor Fitzgerald
02/24/21 Ladenburg
Jaguar Health transferred with Buy, $3.75 target at Ladenburg
LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
06/07/21 Wedbush
MacroGenics price target lowered to $34 from $39 at Wedbush
MRK Merck
$72.16 /

-1.26 (-1.72%)

12/07/21
Fly Intel: Top five analyst downgrades
12/07/21 Guggenheim
Guggenheim downgrades Merck on Keytruda concentration, low pipeline visibility
12/07/21 Guggenheim
Merck downgraded to Neutral from Buy at Guggenheim
11/29/21
Fly Intel: Top five analyst downgrades
MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
NTRA Natera
$92.20 /

+6.06 (+7.04%)

11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
10/19/21 Canaccord
Natera Prospera Lung launch to continue momentum, says Canaccord
10/14/21 Cowen
Natera coverage transferred at Cowen
08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

12/07/21 Needham
NeoGenomics price target lowered to $41 from $48 at Needham
11/05/21 Morgan Stanley
Morgan Stanley downgrades NeoGenomics, sees limited near-term upside
11/05/21 Morgan Stanley
NeoGenomics downgraded to Equal Weight from Overweight at Morgan Stanley
10/14/21 Raymond James
NeoGenomics upgraded to Outperform from Market Perform at Raymond James
NVS Novartis
$80.49 /

-0.03 (-0.04%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
OLMA Olema Oncology
$11.28 /

+0.78 (+7.43%)

12/06/21 Cowen
Olema Oncology assumed with an Outperform at Cowen
12/06/21 Cowen
Olema Oncology assumed with an Outperform at Cowen
10/11/21
Olema Oncology participates in a conference call with JPMorgan
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
OCX OncoCyte
$2.42 /

+0.11 (+4.76%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
ONCY Oncolytics
$1.68 /

+0.07 (+4.35%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

09/28/21
Fly Intel: Top five analyst upgrades
09/28/21 Citi
Puma Biotechnology upgraded to Buy after 40% selloff at Citi
09/27/21 Citi
Puma Biotechnology upgraded to Buy from Neutral at Citi
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
PFE Pfizer
$51.75 /

+0.25 (+0.49%)

12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
SNY Sanofi
$47.51 /

-0.06 (-0.13%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
SGEN Seagen
$148.08 /

+2.06 (+1.41%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
06/15/21 Raymond James
Veracyte initiated with an Outperform at Raymond James
VERU Veru
$6.32 /

+0.14 (+2.27%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VTRS Viatris
$12.50 /

+0.065 (+0.52%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
10/06/21 Jefferies
Zymeworks initiated with a Hold at Jefferies
09/13/21 Raymond James
Zymeworks data continue to outperform Herceptin, says Raymond James
08/05/21 H.C. Wainwright
Zymeworks price target lowered to $44 from $55 at H.C. Wainwright
ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

VTRS Viatris
$12.50 /

+0.065 (+0.52%)

VERU Veru
$6.32 /

+0.14 (+2.27%)

VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SGEN Seagen
$148.08 /

+2.06 (+1.41%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

ONCY Oncolytics
$1.68 /

+0.07 (+4.35%)

OCX OncoCyte
$2.42 /

+0.11 (+4.76%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

NTRA Natera
$92.20 /

+6.06 (+7.04%)

MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

  • 22
    Jul
  • 20
    Oct
  • 18
    Feb
  • 05
    Feb
  • 05
    Feb
  • 07
    Jan
ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

ESALY Eisai
$60.67 /

+0.47 (+0.78%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SGEN Seagen
$148.08 /

+2.06 (+1.41%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

OLMA Olema Oncology
$11.28 /

+0.78 (+7.43%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

NTRA Natera
$92.20 /

+6.06 (+7.04%)

NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

JAGX Jaguar Health
$1.23 /

+0.065 (+5.58%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

ESALY Eisai
$60.67 /

+0.47 (+0.78%)

CNTX Context Therapeutics
$5.63 /

+0.04 (+0.72%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

VTRS Viatris
$12.50 /

+0.065 (+0.52%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

Recommendations
Gilead's lenacapavir opportunity remains intact, says Piper Sandler » 04:58
12/07/21
12/07
04:58
12/07/21
04:58
GILD

Gilead

$69.50 /

-0.04 (-0.06%)

Piper Sandler analyst Do…

Piper Sandler analyst Do Kim keeps a Neutral rating on Gilead Sciences (GILD) with a $77 price target after its partner Merck (MRK) announced an enrollment pause for islatravir Phase 3 studies for HIV-1 prophylaxis. While the islatravir uncertainty puts "lena-isla" estimates at risk, the long-term lenacapavir opportunity remains intact, as Gilead's long-acting capsid inhibitor is on track for early 2022 approval with options internally for a wholly-owned combo, according to management, Kim tells investors in a research note. In addition, the analyst believes an islatravir delay or discontinuation in the PrEP studies offsets the potential delay in a lencapavir combo.

ShowHide Related Items >><<
GILD Gilead
$69.50 /

-0.04 (-0.06%)

GILD Gilead
$69.50 /

-0.04 (-0.06%)

12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
GILD Gilead
$69.50 /

-0.04 (-0.06%)

GILD Gilead
$69.50 /

-0.04 (-0.06%)

GILD Gilead
$69.50 /

-0.04 (-0.06%)

GILD Gilead
$69.50 /

-0.04 (-0.06%)

Monday
Hot Stocks
Kronos Bio first patient dosed in AGILITY Phase 3 trial of entospletinib » 07:13
12/06/21
12/06
07:13
12/06/21
07:13
KRON

Kronos Bio

$11.86 /

+0.21 (+1.80%)

, GILD

Gilead

$69.54 /

-0.16 (-0.23%)

Kronos Bio (KRON)…

Kronos Bio (KRON) announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of entospletinib, a selective inhibitor targeting spleen tyrosine kinase, in combination with standard of care anthracycline and cytarabine chemotherapy. This trial is the first in acute myeloid leukemia to use measurable residual disease as the primary endpoint. Entospletinib is Kronos Bio's lead product candidate, and the company expects to share data from the trial in the second half of 2023. The randomized, double-blind, placebo-controlled trial is designed to assess the efficacy and safety of entospletinib in combination with intensive induction and consolidation chemotherapy in approximately 180 adults who have been newly diagnosed with NPM1-mutated AML. This trial will test the hypothesis, based on robust preclinical and Phase 2 clinical data, that NPM1 mutation leads to dependency on SYK signaling. The primary endpoint of the trial is MRD negative complete response, CR, as measured by molecular detection of mutant NPM1 alleles in bone marrow, which affords a high degree of sensitivity to detect MRD. Kronos Bio acquired entospletinib and another SYK inhibitor, lanraplenib, from Gilead Sciences (GILD) in July 2020. As previously announced, under the agreement with Gilead, the initiation of the Phase 3 trial triggers a $29 million milestone payment from Kronos Bio to Gilead. The payment will be recorded in the fourth quarter.

ShowHide Related Items >><<
KRON Kronos Bio
$11.86 /

+0.21 (+1.80%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

KRON Kronos Bio
$11.86 /

+0.21 (+1.80%)

10/19/21 Cowen
Kronos Bio assumed with an Outperform at Cowen
06/24/21 H.C. Wainwright
Kronos Bio initiated with a Buy at H.C. Wainwright
06/11/21 Piper Sandler
Kronos Bio transferred with Overweight, $50 target at Piper Sandler
GILD Gilead
$69.54 /

-0.16 (-0.23%)

12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
KRON Kronos Bio
$11.86 /

+0.21 (+1.80%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

Initiation
Gilead initiated with a Neutral at Goldman Sachs » 05:44
12/06/21
12/06
05:44
12/06/21
05:44
GILD

Gilead

$69.54 /

-0.16 (-0.23%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter initiated coverage of Gilead Sciences with a Neutral rating and $80 price target. The analyst says that while Gilead is likely to remain the dominant player in HIV with blockbuster Biktarvy, she models for declining sales for the franchise in 2025 and beyond due to loss of exclusivity. Richter is optimistic on Gilead's "ongoing transformation into a more diversified biopharma," but remains on the sidelines pending further evidence of clinical execution.

ShowHide Related Items >><<
GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

GILD Gilead
$69.54 /

-0.16 (-0.23%)

Over a week ago
Periodicals
Moderna CEO expects current vaccines to struggle with omicron, FT says » 06:42
11/30/21
11/30
06:42
11/30/21
06:42
MRNA

Moderna

$368.61 /

+38.78 (+11.76%)

, PFE

Pfizer

$52.40 /

-1.43 (-2.66%)

, BNTX

BioNTech

$362.31 /

+10.86 (+3.09%)

, LLY

Eli Lilly

$254.81 /

-5.79 (-2.22%)

, REGN

Regeneron

$654.26 /

+9.38 (+1.45%)

, GILD

Gilead

$70.64 /

+0.37 (+0.53%)

, VIR

Vir Biotechnology

$40.47 /

+4.48 (+12.45%)

Moderna (MRNA) CEO…

Moderna (MRNA) CEO Stephane Bancel predicted that current vaccines will be much less effective at targeting omicron than previous coronavirus strains and cautioned it would be months before companies could produce variant-specific shots at scale, the Financial Times' Jamie Smyth reports, citing Bancel. "There is no world, I think, where ," Bancel said. "I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to...are like, 'This is not going to be good'." The Fly notes that other companies in the Covid vaccine space include: Pfizer (PFE), BioNTech (BNTX), Eli Lilly (LLY), Regeneron (REGN), Gilead (GILD) and Vir Biotechnology (VIR). Reference Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

11/28/21 Piper Sandler
Moderna has multiple booster candidates to combat omicron, says Piper Sandler
11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
PFE Pfizer
$52.40 /

-1.43 (-2.66%)

11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

11/29/21 UBS
BioNTech to benefit if concerns about omicron variant increase, says UBS
11/10/21
Fly Intel: Top five analyst upgrades
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/10/21 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
REGN Regeneron
$654.26 /

+9.38 (+1.45%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
GILD Gilead
$70.64 /

+0.37 (+0.53%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

11/30/21 H.C. Wainwright
Vir Biotechnology price target raised to $200 from $135 at H.C. Wainwright
11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

Periodicals
Pfizer to ask FDA to authorize 'extra doses' for 16 and 17 year olds, WaPo says » 17:58
11/29/21
11/29
17:58
11/29/21
17:58
PFE

Pfizer

$52.40 /

-1.43 (-2.66%)

, BNTX

BioNTech

$362.31 /

+10.86 (+3.09%)

, MRNA

Moderna

$368.61 /

+38.78 (+11.76%)

, LLY

Eli Lilly

$254.81 /

-5.79 (-2.22%)

, REGN

Regeneron

$654.26 /

+9.38 (+1.45%)

, GILD

Gilead

$70.64 /

+0.37 (+0.53%)

, VIR

Vir Biotechnology

$40.47 /

+4.48 (+12.45%)

Amid the Biden…

Amid the Biden administration's heightened alerts for Americans to get coronavirus vaccines and booster shots to protect themselves against delta and omicron variants of the Covid virus, 16 and 17-year-olds may soon become eligible for "extra doses," wrote, Laurie McGinley and Tyler Pager of the Washington Post. "Pfizer (PFE) and its partner BioNTech (BNTX) are expected to ask the Food and Drug Administration in the coming days to authorize its booster shot for that age group, according to two people familiar with the situation. The regulators are expected to sign off quickly, said the individuals, who spoke on the condition of anonymity because they were not authorized to discuss the issue," added WaPO. The Fly notes that other companies in the Covid vaccine space include: Moderna (MRNA), Eli Lilly (LLY), Regeneron (REGN), Gilead (GILD) and Vir Biotechnology (VIR). Reference Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

11/29/21 UBS
BioNTech to benefit if concerns about omicron variant increase, says UBS
11/10/21
Fly Intel: Top five analyst upgrades
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/10/21 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
MRNA Moderna
$368.61 /

+38.78 (+11.76%)

11/28/21 Piper Sandler
Moderna has multiple booster candidates to combat omicron, says Piper Sandler
11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
REGN Regeneron
$654.26 /

+9.38 (+1.45%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
GILD Gilead
$70.64 /

+0.37 (+0.53%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
10/25/21 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

Hot Stocks
Gilead and AWS team on development and delivery of new medicines for patients » 09:06
11/29/21
11/29
09:06
11/29/21
09:06
AMZN

Amazon.com

$3,503.50 /

-76.25 (-2.13%)

, GILD

Gilead

$70.00 /

-0.09 (-0.13%)

Amazon Web Services an…

Amazon Web Services an Amazon (AMZN) company announced that Gilead Science (GILD), has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization-from biomarker discovery through manufacturing and clinical trial recruitment-and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning transformation project to implement SAP S/4HANA. treat the individual according to their unique needs, not just the disease," said Marc Berson, Senior Vice President and Chief Information Officer at Gilead. "AWS's performance, infrastructure, and scale are the foundations on which we will complete our ERP transformation and become a more efficient, agile, secure, and data-driven business in the cloud." Gilead is reimagining its bioinformatics compute infrastructure in the world's leading cloud. The use of AWS's compute, machine learning, and database capabilities will support the analysis and integration of diverse genomics, imaging, and experimental datasets to support breakthroughs in how Gilead diagnoses and treats diseases. For instance, by securely analyzing deidentified patient genomic data at scale on AWS to reveal patterns, Gilead can uncover insights on how people living with cancer respond to existing therapeutic options, potentially accelerating the discovery of new treatments.

ShowHide Related Items >><<
GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

11/24/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
11/22/21 Guggenheim
Amazon.com assumed with a Buy at Guggenheim
11/19/21 RBC Capital
Williams-Sonoma price target raised to $219 from $199 at RBC Capital
11/18/21 Bernstein
Amazon card news in the U.K. 'clearly a show of strength,' says Bernstein
GILD Gilead
$70.00 /

-0.09 (-0.13%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

Hot Stocks
Gilead, Merck temporarily paused Phase 2 islatravir-lenacapavir trial enrollment » 09:34
11/26/21
11/26
09:34
11/26/21
09:34
GILD

Gilead

$70.10 /

-0.54 (-0.76%)

, MRK

Merck

$82.32 /

-0.48 (-0.58%)

On November 23, Gilead…

On November 23, Gilead Sciences (GILD) and Merck (MRK) announced that they are temporarily pausing enrollment in the Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. "This temporary pause has been implemented out of an abundance of caution, to allow the companies to consider potential protocol adjustments to the trial in light of Merck's announcement on November 18 regarding the decision to stop dosing in the Phase 2 IMAGINE-DR clinical trial evaluating the once-weekly combination of MK-8507 and islatravir. The companies remain optimistic about the future potential of the islatravir and lenacapavir combination regimen to provide a once-weekly oral therapy option for people living with HIV. Participants currently enrolled in this trial will continue to receive the study drug and be monitored per the current protocol. Clinical investigators have been informed of this action and will be notified as soon as any potential protocol adjustments are made. Gilead and Merck remain committed to the collaboration to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead's investigational capsid inhibitor, lenacapavir, and Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, as we work to develop new treatment options to address the unmet needs for people living with HIV," the companies stated. Reference Link

ShowHide Related Items >><<
MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.